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Continuous-time semi-Markov models 
in health economic decision making: 
an illustrative example in heart failure 
disease management
Qi Cao, Erik Buskens, Talitha Feenstra, 
Tiny Jaarsma, Hans Hillege, Douwe Postmus




Continuous-time state transition models may end up having large unwieldy structures when 
trying to represent all relevant stages of clinical disease processes by means of a standard 
Markov model. In such situations, a more parsimonious, and therefore easier to grasp, model 
of a patient’s disease progression can often be obtained by assuming that the future state 
transitions do not only depend on the present state (Markov assumption) but also on the past 
through time since entry in the present state. Despite that these so-called semi-Markov models 
are still relatively straightforward to specify and implement, they are not yet routinely applied 
in health economic evaluation to assess the cost-effectiveness of alternative interventions. To 
facilitate a better understanding of this type of model among applied health economic 
analysts, the first part of this paper provides a detailed discussion of what the semi-Markov 
model entails, and how such models can be specified in an intuitive way by adopting an 
approach called vertical modeling. In the second part of the paper, we use this approach to 
construct a semi-Markov model for assessing the long-term cost-effectiveness of three disease 
management programs for heart failure. Compared to a standard Markov model with the same 
disease states, our proposed semi-Markov model fitted the observed data much better. When 
subsequently extrapolating beyond the clinical trial period, these relatively large differences 
in goodness-of-fit translated into almost a doubling in mean total cost and a 60-day decrease 
in mean survival time when using the Markov model instead of the semi-Markov model. For 
the disease process considered in our case study, the semi-Markov model thus provided a 
sensible balance between model parsimoniousness and computational complexity.  
5.1 INTRODUCTION 
Continuous-time state-transition models (STMs) are increasingly applied in health economic 
evaluation to assess the cost-effectiveness of health care interventions.1-4 Similar to the 
routinely applied discrete-time models, this type of model entails defining a set of discrete 
health states reflecting the different conditions that a patient can be in and a set of transition 
probabilities governing the transitions between these health states.5 However, compared to a 
discrete-time model in which time progresses in fixed increments  (i.e., 1-year cycles), time in 
a continuous-time STM progresses continuously meaning that transitions are no longer 
restricted to occur at the beginning or end of pre-defined time intervals.1,2 As such, the cost-
effectiveness estimates obtained from a continuous-time STM are not affected by the selected 
cycle length, meaning that there is no need to apply corrective measures such as half-cycle 
correction.6 
The best known continuous-time STM is the Markov model, which is based on the 
premise that the future state transitions only depend on the present and are independent of any 
knowledge from the past, such as time since entry into the present state or the sequence of 
prior states leading to the present.7,8 As this assumption greatly simplifies the dependence 
structure, the resulting models can generally still be evaluated analytically.7 A downside of 
this approach is however that without considerably expanding the number of health states a 
standard Markov model is sometimes too restrictive to be able to accurately reflect 
subsequent phases of actual clinical disease processes. 
The above situation for instance occurs in the modeling of diseases such as chronic 
obstructive pulmonary disease or heart failure (HF), where periods of stable chronic disease 
alternate with periods of acute decompensation in which additional medical treatment is 
required and hence the corresponding treatment costs are increased. As the risk of 
experiencing an adverse event generally decreases as the time since the last exacerbation 
increases, the probability of a patient leaving the stable chronic disease state should depend 
on the time since the last exacerbation. To realistically represent such a disease process by 
means of a continuous-time Markov model, one needs to divide the stable chronic disease 
state into a set of embedded states representing increasingly longer time periods since the 
occurrence of the last exacerbation, resulting in a relatively complex model with a large 
number of parameters.2 
Instead of trying to represent complex clinical disease processes by means of a 
standard Markov model, Foucher et al.3 proposed to relax the Markov assumption by 
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assuming that the future state transitions do not only depend on the present but also on the 
past through the time since entry in the present state. Although these so-called semi-Markov 
models 9-11 allow for a more parsimonious representation of complex medical processes in 
situations where some form of time dependency needs to be built into the model, they are not 
yet widely applied in health economic evaluation to assess the cost-effectiveness of 
alternative health care interventions. One of the reasons for this may be that the parameters of 
this type of model do not have a clear clinical interpretation when specified according to the 
cause-specific hazards formulation or the pattern-mixture formulation, which are standard 
approaches for parameterizing semi-Markov models.12 An alternative approach that is not 
hampered by this lack of interpretability is vertical modeling.13 However, as this 
parameterization was only recently introduced in the medical statistical literature, it has not 
yet been extensively discussed in the context of health economic modeling. To facilitate a 
better understanding of the continuous-time semi-Markov model among applied health 
economic analysts, the first part of this paper describes in more detail what such a model 
entails and how such models can be specified in an intuitive way by applying vertical 
modeling. The second part of this paper consists of an illustrative case study in which we use 
vertical modeling to assess the cost-effectiveness of three disease management programs 
(DMPs) for HF. 
  
5.2 SPECIFICATION, ESTIMATION, AND EVALUATION OF CONTINUOUS-
TIME SEMI-MARKOV MODELS  
5.2.1 Definition of the continuous-time semi-Markov model 
A continuous-time STM is a stochastic process {X(t),t≥0} with a finite state space E={1,…,k} 
reflecting how a patient’s disease progresses over time. For a given time s, let ns denote the 
number of transitions within the time interval [0,s], and let v1,…,vns denote the consecutive 
times at which these transitions occurred. The history of the process up to time s can then be 
expressed as H(s)={(vi,X(vi)),0≤i≤ns}, where v0 is set equal to 0 so that X(v0)=X(0) represents 
the starting state of the process. Relative to H(s), the probability that the process will be in 
state h at time t given that it is in state g at time s is defined as  
( , ( )) ( ( ) ( ) , ( )); , ,ghP s t H s P X t h X s g H s s t g h E          <1>  
Finally, the transition intensities are given by 
0
( , ( ))
( ( )) lim ; , ,ghgh t
P t t t H t







      <2> 
meaning that the probability that an individual who is in state g at time t will make a transition 
to state h in the interval [t,t+dt) is approximately equal to αgh(t,H(t))dt for small values of dt.14 
To make this more concrete, consider a patient who, at time 0, has just been 
discharged alive from hospital after having been admitted because of HF. A possible state 
space for describing this patient’s disease progression could be E={discharged alive from 
hospital, HF-related hospital readmission, and dead}. Now, suppose that this patient is 
readmitted at day 115, is discharged alive from hospital at day 130, and is still alive at day 
180. The history of the process up to time 180 would then be equal to H(180)={(0, discharged 
alive from hospital), (115, HF-related hospital readmission), (130, discharged alive from 
hospital)}. In addition, suppose that Pdishosp,dead(180,240|H(180))=0.20 and that 
αdishosp,dead(180|H(180))=0.004. We then know that the probability of this patient being dead 
by time 240 is 20% and that the probability of his/her death occurring within the next week 
(i.e., within the interval [180,187)) is approximately equal to %8.2%1007004.0  . 
For a given starting state distribution, the probability structure of a continuous-time 
STM is completely determined by its transition intensities, which, in turn, are defined in terms 
of the limits of the transition probabilities. Different types of STM can therefore be 
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distinguished by changing the extent to which these probabilities depend on the history of the 
process (i.e., the course of disease). The most straightforward model is the Markov model, 
which is obtained by assuming that the transition probabilities only depend on the present 
(i.e., the fact that the system is in state X(s) at time s). In this paper, we focus on the class of 
semi-Markov models in which, in addition to the present, the transition probabilities depend 
on the past through the time since entry vns in the present state X(s). The definition of the 
transition probabilities in Equation <1> then simplifies to 
( , ( )) ( , ) ( ( ) ( ) , )
s sgh gh n n
P s t H s P s t v P X t h X s g v          <3> 
If, in addition, it holds that Pgh(s,t|vns) is independent of s such that 
( ( ) ( ) , ) ( ( ) ( ) ,0)
s s sn n n
P X t h X s g v P X t v h X s v g            <4> 
the resulting STM is called a homogeneous semi-Markov model (HSMM).15 
Returning to our HF example, the use of an HSMM corresponds to a situation where 
patients who are still alive 50 days after being discharged alive from the index admission  
have the same probability of dying within the next 60 days as patients who are still alive 50 
days after being discharged alive from their second HF-related hospital readmission. If we 
make the additional assumption that this probability does also not depend on the time spent 
within the present state, the resulting STM becomes a Markov model. In terms of our 
example, this would imply that patients who are still alive 50 days after being discharged 
from the hospital have the same probability of dying within the next 60 days as patients who 
are still alive 10 days after being discharged from the hospital. 
 
5.2.2 Statistical model specification 
By substituting Equations <3> and <4> in Equation <2>, it follows that the transition 
intensities of an HSMM can be expressed as  
0 0
( ( ) ( ) ,0) ( ( ) ( ) )
( ( )) lim lim ( )t tn ngh ght u
P X t t v h X t v g P X u u h X u g
t H t u
t u
 
   
       
  
 
  <5> 
Where u=t-vnt denotes the duration in state g. One way of specifying the HSMM would 
therefore be to directly express the transition intensities as functions of the duration u.16 
Although this so-called cause-specific hazards formulation is a standard approach for 
specifying continuous-time STMs, it has the disadvantage that these model entities cannot be 
directly interpreted in terms of survival curves or event frequencies. This may make it 
difficult to discuss the face validity of the model with clinical experts or to communicate the 
results of the cost-effectiveness analysis to decision makers. Alternatively, one could specify 
the HSMM at the level of a set of directly observable quantities that can be uniquely derived 
from the transition intensities. This is the approach taken in both the pattern-mixture 
formulation17, which is based on modeling the time to the next state transition conditional on 
the new state visited, and vertical modeling13, which is based on modeling the new state 
visited conditional on the time spent in the current state. 
Although mathematically feasible, Andersen and Keiding12 criticized the use of the 
pattern-mixture formulation in real-life decision making contexts as it determines how long a 
patient stays in a certain health state conditional on what will happen to him/her in the future, 
which, in reality, is not known beforehand. Vertical modeling, as an alternative formulation, 
does not suffer from this lack of interpretability as it “sticks to this world” and “does not 
condition on the future”.12 In addition, estimation under the pattern mixture formulation is 
time-consuming and difficult because of the need to infer the next state visited for censored 
observations13, while estimation under vertical modeling is still relatively straightforward as 
we will discuss in more detail in the next section. Because of these clear practical advantages, 
vertical modeling is the approach that we consider in more detail in the remainder of this 
paper. 
Let the random variable U, referred to as the sojourn time hereafter, denote the amount 
of time spent in a state before making a transition to a next state, and let the random variable 
D indicate the new state visited. The vertical modeling approach is based on specifying the 
marginal distribution of U and the conditional distribution of D given U, which can both be 
expressed in terms of the transition intensities αgh(t|H(t)).12 In particular, it follows from 
Equation <5> that for an HSMM the cumulative distribution function of the sojourn time for 
each state g ∈ E can be expressed in terms of the transition intensities αgh(u) as  
0




F u P U u X g w dw

             <6>
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Similarly, it holds that the probability mass function of the conditional distribution of the new 
state indicator can be expressed as 
( )













    

       <7> 
By combining Equations <6> and <7>, it follows that the transition intensities can be 
expressed in terms of πgh(u) and Fg(u) as 
( )
















  is 
the probability density function of the sojourn time in state g. This shows that the 
specification of Fg(u) and πgh(u) is indeed sufficient to fully capture an HSMM’s probability 
structure. 
 
5.2.3 Parameter estimation under vertical modeling 
In this paper, we assume that the model is fitted to patient-level data in which the sojourn time 
is either observed exactly or subject to right-censoring within each state. In addition, the 
starting state and all subsequently visited states are assumed to be observed without 
misclassification (i.e., the event indicator should be available to accurately identify the current 
state and the next state visited). The contribution to the likelihood function of the HSMM for 
an individual subject with history H(s) can then be expressed as  
1
1
( ) ( ) 1 ( ) ( ) 1
0
(1 ( )) ( ) ( )
s
n s i i is
n
X v n X v i i X v X v i i
i





          <8> 
if X(vns) is a transient state (i.e., all states for which the probability of leaving exceeds 0) and 
the observations are censored at time s and 
1
1
( ) 1 ( ) ( ) 1
0




X v i i X v X v i i
i





          <9> 
if X(vns) is an absorbing state (i.e., all states for which the probability of leaving is equal to 0) 
and the process terminates at time s=vns. In addition, as the likelihood contributions from the 
different subjects in the dataset are independent, the full likelihood becomes the product of 
the individual likelihoods. 
Because the log-likelihood factors into separate components for Fg(u) and 
πg1(u),…,πgk(u) for each state g ∈ E, parameter estimation under vertical modeling proceeds 
by fitting separate statistical models for the sojourn-time distributions and the future state 
probabilities. Depending on the amount of covariates and on whether extrapolation beyond 
the follow-up period of the clinical trial is required, non-parametric, semi-parametric Cox 
models, or fully parametric survival models can be used to capture the sojourn-time 
distribution in each transient state.18-20 When using parametric survival models, there may be 
clear biological grounds to prefer one specification over another specification. If such 
knowledge is lacking, the best fitting model can alternatively be selected based on a statistical 
criterion, such as the widely applied Akaike information criterion (AIC) or the Bayesian 
information criterion. The future state probabilities can be estimated by applying multinomial 
logistic regression models with the observed sojourn time included as a covariate. Fractional 
polynomials21 or piecewise type splines22 can be used to check for possible non-linearity in 
the relationship between the sojourn time and the future state probabilities. Finally, it should 
be noted that the continuous-time Markov model corresponds to the special case when the 
sojourn-time distributions Fg(u) are exponential and the future state probabilities πgh(u) are 
constant (i.e., independent of the sojourn time u). 
 
5.2.4 Model evaluation under vertical modeling  
In general, evaluating a fitted HSMM to predict costs and health effects is too complex to be 
conducted analytically. 16,23 The simulation process depicted in Figure 1 can then be applied 
to approximate these outcomes numerically. 24 In short, given that the system has just entered 
(or starts in) state g, the sojourn time u is randomly sampled from Fg(u), after which the next 
state is determined in terms of πgh(u). This process is repeated until the system reaches an 
absorbing state or the total simulation time exceeds the time horizon selected for the analysis. 
As usual, the simulation needs to be replicated a large number of times (say 10,000) in order 
to diminish the influence of Monte Carlo error on the results of the cost-effectiveness 
analysis. 
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Similarly, it holds that the probability mass function of the conditional distribution of the new 
state indicator can be expressed as 
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By combining Equations <6> and <7>, it follows that the transition intensities can be 
expressed in terms of πgh(u) and Fg(u) as 
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the probability density function of the sojourn time in state g. This shows that the 
specification of Fg(u) and πgh(u) is indeed sufficient to fully capture an HSMM’s probability 
structure. 
 
5.2.3 Parameter estimation under vertical modeling 
In this paper, we assume that the model is fitted to patient-level data in which the sojourn time 
is either observed exactly or subject to right-censoring within each state. In addition, the 
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if X(vns) is a transient state (i.e., all states for which the probability of leaving exceeds 0) and 
the observations are censored at time s and 
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if X(vns) is an absorbing state (i.e., all states for which the probability of leaving is equal to 0) 
and the process terminates at time s=vns. In addition, as the likelihood contributions from the 
different subjects in the dataset are independent, the full likelihood becomes the product of 
the individual likelihoods. 
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constant (i.e., independent of the sojourn time u). 
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Figure 1: The process of simulating from a continuous-time HSMM   
5.3 ILLUSTRATIVE CASE STUDY 
The Coordinating study evaluating Outcomes of Advising and Counseling in Heart failure 
(COACH) is a multicenter, randomized controlled trial in which 1,023 patients who were 
discharged alive from the hospital after having been admitted for reasons related to HF were 
randomly assigned to either the control group (follow-up by a cardiologist) or one of the two 
intervention groups with basic or intensive additional support by a nurse specialized in the 
management of HF patients.25,26 The average age of the study population was 71 years and 
38% was female. During the 18 months follow-up period, 411 patients (40%) reached the 
primary endpoint of death or HF-related hospital readmission, of whom 260 (63%) were 
readmitted because of HF. The all-cause mortality rate was 29% in the control group, 27% in 
the basic support group, and 24% in the intensive support group. The study complied with the 
Declaration of Helsinki, and a central appointed ethics committee approved the research 
protocol. Informed consent was obtained from all subjects.  
In this case study, we will illustrate how vertical modeling can be applied to construct 
an HSMM for assessing the long-term cost-effectiveness of the three disease management 
programs (DMPs) considered in COACH. We will also compare the goodness-of-fit of our 
proposed model against that of a Markov model to explore to what extent the use of the 
HSMM results in more reliable cost-effectiveness estimates.  
 
5.3.1 Statistical model specification and parameter estimation 
The state space for the two models was as follows (Figure 2): discharged alive (state 1), HF-
related hospital readmission (state 2), and dead (state 3). To specify the sojourn-time 
distributions of the two transient health states, the available patient-level data was first 
transformed into long format where each row represents one patient at risk of making a 
transition. Patients who were readmitted at least once have been at risk for subsequent 
transitions during different periods of their follow-up, meaning that these patients are 
represented multiple times in this dataset. For example, a patient entering state 1 at some 
point during his or her follow-up was from this point onwards at risk of making a transition to 
either state 2 or state 3. For this patient, a row was therefore included in the dataset with the 
event time set equal to the amount of time spent in state 1 (or the time to censoring if this 
observation was subjected to right-censoring), a censoring indicator set equal to 1 if the 
transition was observed and 0 if the transition was censored, and a new state indicator set 
equal to the next state visited (if the transition was observed). All time variables were 
recorded in days. 
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Figure 2: Schematic representation of the structure of both our HSMM and the Markov model 
 
Using this dataset, the estimation of the HSMM proceeded as follows. First, the 
goodness-of-fit of six different parametric survival models (log-normal, exponential, log-
logistic, Weibull, Gaussian, and logistic) with the event time and censoring indicator as 
defined previously and the treatment indicator included as a covariate was compared in terms 
of the AIC to obtain the best fitting models for F1(u) and F2(u). This resulted in a log-normal 
distribution for both the sojourn time in state 1 and the sojourn time in state 2. The future state 
probabilities π13(u) and π23(u) were estimated by fitting a logistic regression model to the 
observed binary outcomes of out-of-hospital death and in-hospital death, respectively, with 
the treatment indicator and the sojourn time included as the two covariates. Possible non-
linearity in the associations between sojourn time and these two future state probabilities were 
assessed using a closed test procedure based on fractional polynomials, with the significance 
levels for the variable inclusion and for comparing the fit of different fractional polynomial 
functions both set equal to 0.05.27 For out-of-hospital death, a quadratic relationship was 
found between the sojourn time and the log-odds of this future state probability. Possible 
interaction between the treatment indicator and the included sojourn time effects was also 
tested for, but none of these interaction terms were statistically significant. No association 
was found between the sojourn time and the log-odds of in-hospital mortality. This latter 
probability was therefore assumed to be a constant, with values equal to 0.20, 0.14, and 0.13 
for patients in the care-as-usual, basic support, and intensive support group, respectively. For 
the Markov model, F1(u) and F2(u) were estimated by fitting two exponential distributions, 
while the future state probabilities were estimated by fitting two logistic regression models 
that did not include any sojourn time effects. The results of the statistical model specification 
and parameter estimation for both the HSMM and the Markov model are summarized in 
Table 1. All the above analyses were performed using R version 3.1.1 (R Foundation for 
Statistical Computing, Vienna, Austria). 
 
5.3.2 Goodness-of-fit of the estimated sojourn-time distributions 
Figure 3 and Figure 4 display, per treatment group, the goodness-of-fit of F1(u) and F2(u) for 
both our proposed HSMM and the Markov model. The observed sojourn-time distributions 
were obtained by taking the complement (i.e., one minus) of the Kaplan-Meier curves of the 
time spent in each of the health states. From these figures, we can conclude that the sojourn-
time distributions of our proposed HSMM fit the empirical data much better than the sojourn-
time distributions of the Markov model. 
 
5.3.3 Model validation 
The performance on overall survival of both our proposed HSMM and the Markov model was 
internally validated by comparing the predicted (average across 100,000 simulation runs) 
versus the observed (Kaplan-Meier estimate) survival curves.28 As is shown in Figure 5, the 
predicted survival curves obtained from the HSMM closely matched the observed survival 
curves, whereas a clear deviation from the observed survival curves was observed while using 
the Markov model.  
 
5.3.4 Cost-effectiveness analysis 
To evaluate the long-term cost-effectiveness of the three DMPs considered in COACH, the 
simulation process depicted in Figure 1 was repeated 100,000 times with the discharged alive 
state as the starting state and survival time as the measure of health effect. The maximum 
follow-up time for each simulation run was set to be 5 years. As our case study is illustrative 
in nature, we did neither consider patient heterogeneity nor stochastic uncertainty. Our results  
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Note: Care-as-usual is the reference category for TT ; θ(π)=log(π/(1-π)) is the logit function 
 
Figure 3: Goodness-of-fit of the sojourn-time distributions for the discharged alive state for care-as-usual 
(left), basic support (middle), and intensive support (right). The grey area band widths reflect the 95% 
confidence intervals of the observed sojourn-time distributions 
 
 
Figure 4: Goodness-of-fit of the sojourn-time distributions for the HF-related hospital readmission state 
for care-as-usual (left), basic support (middle), and intensive support (right). The grey area band widths 





5Continuous-time health economic modeling
99
Table 1: The specification of the regression models and the results of the parameter estimation for both 





































































































































































































































































Note: Care-as-usual is the reference category for TT ; θ(π)=log(π/(1-π)) is the logit function 
 
Figure 3: Goodness-of-fit of the sojourn-time distributions for the discharged alive state for care-as-usual 
(left), basic support (middle), and intensive support (right). The grey area band widths reflect the 95% 
confidence intervals of the observed sojourn-time distributions 
 
 
Figure 4: Goodness-of-fit of the sojourn-time distributions for the HF-related hospital readmission state 
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Figure 5: Observed versus predicted survival curves for care-as-usual (left), basic support (middle), and 
intensive support (right). The grey area band widths reflect the 95% confidence intervals of the observed 
survival curves 
 
Table 2: Results of the cost-effectiveness analysis. In the ICER column, basic support is compared against 
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therefore represent the expected 5-year cost-effectiveness of the three DMPs in a population 
with the same distribution of covariates as in the COACH study population. 
 To obtain the cost attached to the discharged alive state, we divided the mean 
aggregated intervention costs taken from our previously conducted trial-based economic 
evaluation29 by the average observed out-of-hospital days within the COACH follow-up 
period. This resulted in a state cost of €0.86 per day for care-as-usual, €1.56 per day for basic 
support, and €2.34 per day for intensive support. The cost attached to the HF-related hospital 
readmission state was set to be €769 per day and was assumed to be the same for all three 
DMPs.  
Table 2 depicts the results of the cost-effectiveness analysis using both our proposed 
HSMM and the Markov model with costs and survival time discounted at respective annual 
rates of 4% and 1.5% as described in the Dutch manual for costing.30 These results show that 
the differences in model fit between the HSMM and the Markov model translate into 
relatively large differences with respect to the estimates of the mean total cost, the mean 
survival time, and the mean incremental cost-effectiveness ratio (ICER) between intensive 
support and basic support. 
In the above analysis, we assumed that the level of care provided within each 
treatment group was the same for the clinical trial period as for the period between 18 months 
and 5 years. To investigate the impact of this assumption on the results of the cost-
effectiveness analysis, we reduced, for each DMP, the level of care provided after the first 18 
months to a half-yearly visit and a yearly visit to the cardiologist. For the period between 18 
months and five years, this resulted in state costs for the discharged alive state of €0.60 per 
day and €0.30 per day, respectively. For the HSMM, these reductions in state costs reduced 
the ICER between intensive support and basic support from 15,825 (base case) to 11,167 
(half-yearly follow-up) and 11,083 (yearly follow-up).  For the Markov model, this ICER 
reduced from 20,406 (base case) to 17,318 (half-yearly follow-up) and 17,259 (yearly follow-
up). In addition, we repeated the analysis with annual discount rates of 3% for both costs and 
survival time, but this hardly had any impact on the results of the cost-effectiveness analysis. 
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Figure 5: Observed versus predicted survival curves for care-as-usual (left), basic support (middle), and 
intensive support (right). The grey area band widths reflect the 95% confidence intervals of the observed 
survival curves 
 
Table 2: Results of the cost-effectiveness analysis. In the ICER column, basic support is compared against 
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In reality, a patient’s future disease status may depend on disease history, co-morbidity, and 
many other factors through complex interactions. Without considerably expanding the 
number of health states, such interactions may however be difficult to capture by means of a 
standard Markov model. Although in such situations a more parsimonious representation of a 
patient’s disease progression can often be obtained by replacing the Markov model by an 
HSMM, this latter type of model is not yet routinely applied in health economic evaluation to 
assess the cost-effectiveness of alternative health care interventions. To facilitate a better 
understanding of this model among applied health economic analysts, this paper provided a 
detailed discussion on how the different parameters of such a model can be specified using 
vertical modeling. We subsequently illustrated the use of this approach in a case study related 
to the disease management of HF. 
To illustrate the potential biases resulting from not including any form of time 
dependency in the definition of the transition intensities, we fitted in our case study both an 
HSMM and a Markov model. The subsequent assessment of the goodness-of-fit showed that 
especially for the sojourn-time distribution of the discharged alive from hospital state, the 
Markov model yielded a poor fit with the observed data. As a consequence of this, the use of 
the Markov model resulted in an overestimation of the mean survival time for the COACH 
study period (Figure 5) and an underestimation of the mean survival time when extrapolating 
these curves to a 5-year period (Table 2). The HSMM, in contrast, closely resembled the 
observed data for all of the performed goodness-of-fit tests. In terms of cost-effectiveness, 
these relatively large differences in goodness-of-fit translated into almost a doubling in mean 
total cost and a 60-day decrease in mean survival time when using the Markov model instead 
of the HSMM. 
The cost-effectiveness analysis that we conducted as part of our case study has two 
limitations. First, since the aim of this case study was to illustrate model specification and 
parameter estimation under vertical modeling, and not to conduct a full economic evaluation 
in support of a real-life decision problem, we felt that it would be sufficient to conduct a 
relatively straightforward deterministic analysis. We obviously recognize that in applied 
health economic evaluation it is a standard practice to complement the results of such a 
deterministic assessment with probabilistic sensitivity analyses to evaluate how uncertainty in 
the model inputs accumulates in overall uncertainty in the modeled outcomes.31 One way to 
obtain a joint probability distribution for the parameters of the sojourn-time distributions and 
the future state probabilities under vertical modeling would be to apply bootstrapping, which 
is relatively straightforward to implement when patient-level data is available.32 Second, the 
regression models that we used to specify the different entities of our HSMM (i.e., the 
parametric survival models for the sojourn-time distributions and the logistic regression 
models for the future state probabilities) did not contain any covariates apart from the 
treatment indicator (for all models) and the sojourn time (to estimate the probability of out-of-
hospital death). Our model therefore does not allow for the assessment of patient 
heterogeneity as described by Groot Koerkamp et al..33 This potential limitation, however, can 
easily be overcome by adding patient characteristics, such as sex, age, and comorbidity as 
additional covariates in the regression models. For a more concrete and extensive discussion 
on how to deal with patient heterogeneity within the context of a health economic evaluation, 
we refer the reader to Grutters et al..34  
The fundamental assumption underlying the HSMM is that the future state transitions 
only depend on the history of the process through the time since entry in the present state. A 
limitation of this type of model is therefore that the possible influence that other time scales 
such as general ageing of an individual may have on a patient’s disease progression are 
ignored. For the modeling of chronic diseases, this could for instance result in an 
overestimation of the mean survival time when age is not included as a fixed-time covariate in 
the regression models, which would allow us to update this variable each time that a transition 
into a new state occurs. Alternatively, one could overcome this limitation by switching from a 
homogeneous to a non-homogeneous semi-Markov model, in which age would then be 
included as a time-dependent covariate.35 The specification and estimation of this latter type 
of model is however far less straightforward as the transition intensities as well as all 
functionals directly derived from these intensities then become functions of both the time 
since entry in the model and the time since entry in the present state. Another way to relax the 
assumptions behind the HSMM would be to let the transition intensities not only depend on 
the time since entry in the present state but also on how often this state has previously been 
visited. For example, Bakal et al.36 have recently established that the time between 
consecutive HF-related hospitalizations decreases as the number of previous admissions 
increases. When using vertical modeling, such dependencies can be easily included in the 
model specification of the sojourn-time distributions by including the number of previous HF 
hospitalizations as an additional covariate in the regression equations. However, as the 
resulting STM is then strictly speaking no longer a semi-Markov model, we refrained from 
doing so in our case study. 
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5.4 DISCUSSION 
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obtain a joint probability distribution for the parameters of the sojourn-time distributions and 
the future state probabilities under vertical modeling would be to apply bootstrapping, which 
is relatively straightforward to implement when patient-level data is available.32 Second, the 
regression models that we used to specify the different entities of our HSMM (i.e., the 
parametric survival models for the sojourn-time distributions and the logistic regression 
models for the future state probabilities) did not contain any covariates apart from the 
treatment indicator (for all models) and the sojourn time (to estimate the probability of out-of-
hospital death). Our model therefore does not allow for the assessment of patient 
heterogeneity as described by Groot Koerkamp et al..33 This potential limitation, however, can 
easily be overcome by adding patient characteristics, such as sex, age, and comorbidity as 
additional covariates in the regression models. For a more concrete and extensive discussion 
on how to deal with patient heterogeneity within the context of a health economic evaluation, 
we refer the reader to Grutters et al..34  
The fundamental assumption underlying the HSMM is that the future state transitions 
only depend on the history of the process through the time since entry in the present state. A 
limitation of this type of model is therefore that the possible influence that other time scales 
such as general ageing of an individual may have on a patient’s disease progression are 
ignored. For the modeling of chronic diseases, this could for instance result in an 
overestimation of the mean survival time when age is not included as a fixed-time covariate in 
the regression models, which would allow us to update this variable each time that a transition 
into a new state occurs. Alternatively, one could overcome this limitation by switching from a 
homogeneous to a non-homogeneous semi-Markov model, in which age would then be 
included as a time-dependent covariate.35 The specification and estimation of this latter type 
of model is however far less straightforward as the transition intensities as well as all 
functionals directly derived from these intensities then become functions of both the time 
since entry in the model and the time since entry in the present state. Another way to relax the 
assumptions behind the HSMM would be to let the transition intensities not only depend on 
the time since entry in the present state but also on how often this state has previously been 
visited. For example, Bakal et al.36 have recently established that the time between 
consecutive HF-related hospitalizations decreases as the number of previous admissions 
increases. When using vertical modeling, such dependencies can be easily included in the 
model specification of the sojourn-time distributions by including the number of previous HF 
hospitalizations as an additional covariate in the regression equations. However, as the 
resulting STM is then strictly speaking no longer a semi-Markov model, we refrained from 
doing so in our case study. 
Chapter 5
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To conclude, the continuous-time semi-Markov model provides a sensible balance 
between model parsimoniousness and computational complexity for many clinical disease 
processes. In this paper, we described and illustrated how such models can be estimated from 
right-censored time-to-event data. Future research effort may be directed at how one could 
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